Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children

Otto Laub 1†, Georg Leipold 2†, Antoaneta A. Toncheva 3†, David Peterhoff 4,5†, Sebastian Einhauser 4†, Patrick Neckermann 4, Natascha Borchers 3, Elisangela Santos-Valente 3, Parastoo Kheiroddin 4, Heike Buntrock-Döpke 3,6, Sarah Laub 4, Patricia Schöberl 3,6, Andrea Schweiger-Kabesch 3, Dominik Ewald 7, Michael Horn 8, Jakob Niggel 9, Andreas Ambrosch 10, Klaus Überla 11, Stephan Gerling 3, Susanne Brandstetter 3,6, Ralf Wagner 4,5†, Michael Kabesch 3,6† and Corona Virus Antibodies in Children from Bavaria (CoKiBa) Study Group

1 Pediatric Office Laub, Rosenheim, Germany, 2 Pediatric Office Dr. Leipold, Regensburg, Germany, 3 University Children’s Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Regensburg, Germany, 4 Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany, 5 Institute of Clinical Microbiology and Hygiene, University Hospital, Regensburg, Germany, 6 Member of the Research and Development Campus Regensburg (WECARE) at the Hospital St. Hedwig of the Order of St. John, Regensburg, Germany, 7 Pediatric Office Dr. Heuschmann & Dr. Ewald, Regenstauf, Germany, 8 Pediatric Office Dr. Horn, Schönau, Germany, 9 Maganamed Limited, Regensburg, Germany, 10 Institute of Laboratory Medicine, Microbiology and Hygiene, Hospital of the Order of St. John, Regensburg, Germany, 11 Institute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany

Background: Children and youth are affected rather mildly in the acute phase of COVID-19 and thus, SARS-CoV-2 infection infection may easily be overlooked. In the light of current discussions on the vaccinations of children it seems necessary to better identify children who are immune against SARS-CoV-2 due to a previous infection and to better understand COVID-19 related immune reactions in children.

Methods: In a cross-sectional design, children aged 1–17 were recruited through primary care pediatricians for the study (a) randomly, if they had an appointment for a regular health check-up or (b) if parents and children volunteered and actively wanted to participate in the study. Symptoms were recorded and two antibody tests were performed in parallel directed against S (in house test) and N (Roche Elecsys) viral proteins. In children with antibody response in either test, neutralization activity was determined.

Results: We identified antibodies against SARS-CoV-2 in 162 of 2,832 eligible children (5.7%) between end of May and end of July 2020 in three, in part strongly affected regions of Bavaria in the first wave of the pandemic. Approximately 60% of antibody positive children (n = 97) showed high levels (>97th percentile) of antibodies against N-protein, and for the S-protein, similar results were found. Sufficient neutralizing activity was detected for only 135 antibody positive children (86%), irrespective of age and sex. Initial COVID-19 symptoms were unspecnific in children except for the loss of smell and taste and unrelated to antibody responses or neutralization capacity. Approximately 30%
INTRODUCTION

Early in the COVID-19 pandemic, children and adolescents were thought to be important transmitters of the disease but were also believed to be only mildly affected (1). Later, evidence increased that children are not major spreaders (2–4). However, a pediatric multiorgan immune syndrome in children and youths was reported (5), occurring weeks to months after the SARS-CoV-2 infection, also in children with mild or no symptoms in the initial phase of the disease. Recent studies linked PIMS to the presence of antibodies to SARS-CoV-2 and some authors suggested that high levels of antibodies against SARS-CoV-2 may in fact contribute to the occurrence of the full-fledged syndrome (6). These observations indicate that immune reactions to SARS-CoV-2 exposure may differ, at least in strength, between children and adults.

When vaccination for SARS-CoV-2 was first administered to adults, stronger systemic vaccination reactions to the vaccine were reported in younger individuals (7). In some of our cases, high antibody levels were already observed directly after vaccination when these symptoms occurred (own observation), suggesting a possibility that these individuals may have had an unnoticed SARS-CoV-2 infection previously. With vaccination of children against SARS-CoV-2 in sight, it is important to better identify those that were already infected and to improve our understanding of SARS-CoV-2 related immune responses in children overall.

In many children allegedly mild or inapparent infections occurred and PCR testing was performed rarely. Therefore, we screened a large number of children in rather severely affected areas of Bavaria (Southern Germany) for symptoms as well as overall and neutralizing antibody levels against SARS-CoV-2 in the first pandemic wave in spring of 2020, in a population-based approach.

METHODS

Study Design and Population

In a cross-sectional design we investigated children from three distinct regions of South East Germany to assess the true prevalence of SARS-CoV-2 infections in areas with very differently reported infection rates by antibody testing. We established a network of pediatricians who volunteered to take part in the study and focused on three areas/counties within Bavaria with very high, moderate, and average infection rates as indicated by positive PCR tests per 100,000 inhabitants according to the Robert Koch Institute, the German center for disease prevention (Figure 1). The assessment and sample collection took place in three study areas: Tirschenreuth; Regensburg city and county; and Oberbayern/ alpine region from May 22nd to July 22nd, 2020. In areas where the number of willful study participants exceeded the capacity of local pediatricians, a study team supported sample collections.

Invitation to participate for children aged 1–14 years was based on two approaches: (a) All children of that age group who were scheduled for a prevention program visit in 2020 with the respective pediatrician were invited to participate (random selection) and (b) all children of families who actively wanted to participate were also tested (own intention to participate). In approach (b), also siblings older than 14 years were allowed to participate in the study, as for ethical reasons, children older than 14 could not be excluded from antibody testing if families presented them together with younger siblings for testing. The study was approved by the Ethics Committee of the University of Regensburg (file-number: 20-1865-101).

Data Collection and Management

All data were collected in an online survey using self-administered parental questionnaires. The questionnaires can be obtained upon request from the authors. All acquired data was fully anonymized and only accessible at an individual level to the participant using an individual code on the Qnome platform (www.qnome.eu) as previously described in detail (8). Clinical data was entered by the parents in an online survey. That way, anonymization of data on the level of the dataset was achieved while the test values were directly accessible to parents.

SARS-CoV-2 Antibody Tests

Blood was taken from all participants by venipuncture. Specific antibody response to SARS-CoV-2 was evaluated by the use of two different test kits: the commercially available, licensed qualitative Elecsys Anti-SARS-CoV-2 (Roche Diagnostics, Rotkreuz, Switzerland; https://diagnostics.roche.com) with a sensitivity of 99.5% and a specificity of 99.8%, according to the manufacturer; and a validated and published in-house ELISA with a sensitivity of 96% and a specificity of 99.3% as previously reported (9). The Elecsys Anti-SARS-CoV-2 assay does not discriminate between the antibody type(s) present and can detect IgA, IgM, and IgG. The test is based on a recombinant nucleocapsid (N) antigen and has a cutoff value of 1.0 (S/Co). The
in-house ELISA is based on SARS-CoV-2 S-protein’s receptor-binding domain, quantifies total IgG and has a cutoff value of 1.0 (S/Co). The detected reactivity correlates with the SARS-CoV-2 neutralization titer as described previously (9). All samples with S/Co <1.0 were considered negative.

**SARS-CoV-2 Neutralization Test**
Neutralizing antibodies were evaluated by titration of sera against SARS-CoV-2 pseudotyped Vesicular Stomatitis Virus (VSV). The test is based on VSV-ΔG*FLuc pseudotyped with SARS-CoV-2-Spike-ΔER, which correlates with SARS-CoV-2 neutralization as described previously (10, 11). Pseudoviral titers were determined by limited dilution and fluorescence microscopy. For all samples, a fixed inoculum of 25,000 ffu was neutralized for 1 h and luciferase activity was determined 20 h post infection of HEK293T-ACE2*cells. IC50 values were fitted using the algorithm: ‘log (inhibitor) vs. normalized response’. Data were analyzed and Spearman’s correlations (R) were calculated in GraphPad Prism 8 software (GraphPad Software, San Diego, USA).

**Statistical Analyses**
Descriptive statistics were calculated using frequencies (percentages) for categorical data and median (interquartile range) for metric data. Participants’ characteristics and symptoms are presented stratified by antibody response. Differences between groups were analyzed using χ²-tests for categorical variables and t-test for independent groups, respectively. All analyses were performed using SPSS.23.

**RESULTS**
Overall, 2,934 children participated in the study of whom 2,906 were tested successfully with at least one of the two applied antibody tests and 2,832 (96.5%) had also entered necessary study data in the online tool. Demographic data of the children participating in the study are given in Table 1 and locations of test-centers across counties are depicted in Figure 1. Overall, 161 participants were classified seropositive with any test*, of which 158 were ELISA positive and 139 showed a positive ELECSYS signal, yielding a total concordance of 83.9 % (n = 135 positive in both tests) and a total discordance of 16.1 %

---

*Figure 1: Map of Bavaria with location of centers contributing to the survey (red dots) and COVID-19 prevalence until July 2020 (color coded by county). Number for overall, negatively and positively tested children are given in the circle chart.
TABLE 1 | Characteristics of study participants stratified for antibody (AB) test result.

| General characteristics | Negative AB test (N = 2,670) | Positive AB test (N = 162) | p |
|-------------------------|-------------------------------|---------------------------|---|
| Study participation due to... |                               |                           |   |
| random selection (health check-up), % (N) | 66.0 (1,763) | 32.1 (52) | <0.001* |
| own intention to participate, % (N) | 34.0 (907) | 67.9 (110) |     |
| Sex (male), % (N) | 51.7 (1,380) | 50.6 (82) | 0.792 |
| Age (years) (Md, IQR) | 7 (4.0–10.0) | 8 (4.7–11.0) | 0.070 |
| (range 0–17) (range 0–16) |                               |                           |   |
| Any chronic disease, % (N) | 12.3 (329) | 9.3 (15) | 0.247 |

Does your child usually attend...

| Nursery, % (N) | 6.1 (163) | 4.9 (8) |   |
| Kindergarten, % (N) | 27.5 (733) | 23.5 (38) |   |
| Elementary school, % (N) | 30.3 (809) | 29.0 (47) |   |
| Secondary school (Mittelschule), % (N) | 4.9 (130) | 9.9 (16) | <0.001* |
| Secondary school (Realschule), % (N) | 8.5 (227) | 11.1 (18) |   |
| Grammar school, % (N) | 11.0 (295) | 9.9 (16) |   |
| School for special needs, % (N) | 0.6 (17) | 1.2 (2) |   |
| None of them, % (N) | 11.1 (296) | 10.5 (17) | 0.138 |

| SARS-CoV-2 PCR testing, % (N) | 8.8 (234) | 17.9 (29) | <.001* |
| Positive SARS-CoV-2 PCR test, % (N) | 0.2 (6) | 9.3 (15) | <0.001* |
| Hospitalization due to COVID-19, % (N) | 0.2 (6) | 1.2 (2) | 0.019* |
| Household member COVID-19, % (N) | 6.0 (161) | 47.5 (77) | <0.001* |
| Any symptom, % (N) | 70.1 (1,871) | 76.5 (124) | 0.080 |

*p < 0.05; chi² test, t-test for independent groups. IQR, interquartile range. Md, median.

Strong regional differences were observed in the prevalence of SARS-CoV-2 antibodies in children (Figure 1). Overall, children in the heavily affected county of Tirschenreuth (with 1,638 positive PCR tests/100,000 inhabitants when the survey was performed) had positive antibody response 3–4 times more often than in the two other test regions, with 586 positive PCR tests/100,000 inhabitants in Regensburg and 1,111 positive PCR tests/100,000 inhabitants in Rosenheim (September 2020). When only those children randomly selected [approach (a)] and only one child (the youngest) per family were included in the analysis, 7.2% of tested children were positive in Tirschenreuth, 3.1% in Regensburg and 1.8% in Oberbayern/Alpine region. In those who participated on their own intention, e.g., due to symptoms that may have been related to COVID-19 or suspected contact to a COVID-19 patient [approach (b)], 15.9% were found positive in Tirschenreuth, 2.3% in Regensburg and 7.8% in Oberbayern/Alpine region, again taking only one child per family into account.

The older the children, the more positive SARS-CoV-2 tests were found, with 4.9% positive in the 0–6 year-olds (n = 1,299), 5.7% in the 7–10 year-olds (n = 849) and 7.3% positive in the 11–17 year-olds (n = 684). Children with chronic diseases tended to be slightly less often positive (4.3% of 344) than those without chronic diseases (5.9% of 2,488). Within the study population, only 263 children had already received a SARS-CoV-2 PCR test previously and 21 had a positive test result. Of these, 15 individuals showed elevated antibody responses (71.4%) while in 6 subjects no antibody response in any of the two tests could

FIGURE 2 | Comparison between the N protein directed Elecsys Anti-SARS-CoV-2 assay (total Ig) and the S protein directed in-house SARS-CoV-2 assay detecting IgG (IgG) in the total study population (N = 2,832). Strong dotted lines represent the assay cutoff values, ±10% borderline intervals (gray areas). Signal-to-cutoff (S/Co) ratios are given for both assays.

(n = 23 ELECSYS-positive/ELISA-negative; n = 3 ELECSYS-positive/ELISA) (Figure 2). A positive result in at least one of the two tests defined a positive case.
be found. Two hundred and thirty-eight children lived in a household with a positively tested family member and of these, 32.4% developed antibodies against SARS-CoV-2. Thus, living with a SARS-CoV-2 positive family member is the single most prominent association with a SARS-CoV-2 infection in children in our study population. We assessed symptoms potentially related with SARS-CoV-2 infections in our study population but found very few specific features (other than the loss of smell and taste) which would allow to discriminate COVID-19 from common viral infections in children (Table 2).

Despite the good level of concordance (83.9%) between the occurrence of N-protein specific (Roche Elecsys) and S-protein specific antibodies (in-house ELISA), N-specific titers (ELECSYS) did not correlate with our in-house S-protein ELISA in the overall analysis (Figure 2). Considering this obvious discordance regarding N- and S-protein specific antibody titers, the positive population in any test with sufficient material for further testing ($n = 161$) was analyzed for neutralizing antibodies (nAbs).

In the following neutralizing activity was detected for $n = 135$ participants, providing a total concordance of 95.7% ($n = 133$ positive; $n = 21$ negative) and a discordance of 4.3% ($n = 2$ N-seropositive/neutralization-negative; $n = 5$ N-seronegative/neutralization-positive) of the Elecsys result with the presence of nAbs. For comparison, the ELISA showed 83.2% concordance ($n = 133$ positive; $n = 1$ negative) and 16.8% discordance ($n = 25$ S-seropositive/neutralization-negative; $n = 2$ S-seronegative/neutralization-positive) with the result of the neutralization assay (Figure 3 and Supplementary Table 1).

As internal control, $n = 81$ randomly chosen negative sera (matching the age and sex distribution of the positive population) were tested for the presence of neutralizing antibodies, of which none exhibited a positive result yielding a specificity of 100% (Supplementary Figure 1).

Correlating (Spearman) the quantitative results of the three assays showed a significant correlation for each pair, while the ELISA correlated best ($R = 0.62$) with the IC-50 of the neutralization assay, the quantitative readout of the Elecsys showed inferior correlation with both the ELISA ($R = 0.46$) and the neutralization ($R = 0.50$). This was not surprising, as the manufacturer doesn’t recommend any quantitative readout of the ELECSYS assay. Furthermore, no significant effects could be found on any of the three (quantitative) test results regarding age or sex of the participants (Supplementary Figure 2). Neither antibody levels nor neutralization capacity did correlate with any of the classical symptoms named in Table 2 (detailed analysis in Supplementary Figure 3).

**DISCUSSION**

In our study, performed in regions of Germany with a relatively high incidence of COVID-19 in adults in the first phase of the pandemic, approximately 6% of tested children were positive for SARS-CoV-2 antibodies in two tests directed against the N- and S-proteins of the virus. Symptoms of COVID-19 were found to be rather unspecific in children while antibody response was strong in most cases. SARS-CoV-2 neutralization capacity was independent of age, sex or symptoms in those children with antibodies and absent in those without antibodies.

This study showed an unexpected high prevalence rate of SARS-CoV-2 infections in children in Germany in the first wave, comparable to similar studies in Germany (12). The antibodies

---

**Table 2** | Symptoms of study participants after antibody measurement: stratified for antibody (AB) test result.

| Symptoms                        | Negative AB test ($N = 2,670$) | Positive AB test ($N = 162$) | $p$  |
|---------------------------------|---------------------------------|------------------------------|------|
| No symptoms, % (N)             | 30.1 (804)                      | 23.5 (38)                    | 0.072|
| Runny nose, % (N)              | 42.5 (1,135)                    | 32.7 (53)                    | 0.014*|
| Sore throat, % (N)             | 28.2 (753)                      | 18.5 (30)                    | 0.007*|
| Headache, % (N)                | 24.3 (648)                      | 24.1 (39)                    | 0.955 |
| Dizziness, % (N)               | 6.5 (173)                       | 4.9 (8)                      | 0.436 |
| Exhaustion/ fatigue, % (N)     | 24.0 (640)                      | 25.3 (41)                    | 0.699 |
| Muscle aches, % (N)            | 14.0 (373)                      | 16.0 (26)                    | 0.480 |
| Inflammation of the eyes, % (N)| 4.4 (117)                       | 3.1 (5)                      | 0.430 |
| Loss of smell, % (N)           | 1.0 (27)                        | 4.9 (8)                      | <0.001*|
| Loss of taste, % (N)           | 2.4 (64)                        | 6.8 (11)                     | 0.001*|
| Shortness of breath, % (N)     | 5.1 (137)                       | 3.7 (6)                      | 0.420 |
| Coughing, % (N)                | 41.0 (1,096)                    | 30.9 (50)                    | 0.010*|
| Fever, % (N)                   | 37.6 (1,004)                    | 38.3 (62)                    | 0.865 |
| Chills, % (N)                  | 7.3 (194)                       | 3.7 (6)                      | 0.086 |
| Rash, % (N)                    | 5.3 (142)                       | 2.5 (4)                      | 0.111 |
| Diarrhea, % (N)                | 16.5 (441)                      | 13.0 (21)                    | 0.235 |
| Nausea, % (N)                  | 11.4 (304)                      | 9.9 (18)                     | 0.556 |
| Loss of appetite/difficulty feeding, % (N) | 11.2 (298) | 5.6 (9) | 0.026* |
| Other symptoms, % (N)          | 2.5 (66)                        | 2.5 (4)                      | 0.998 |

*$p < 0.05$; chi² test.
in our study were determined approximately 2 months after the peak of the first pandemic wave. Despite the closing of schools, kindergartens, and nurseries very early on in the pandemic in Germany, a surprisingly high number of children showed antibodies in our study. One possible explanation for that could be that many parents who participated in the study suspected a coronavirus infection in their children due to symptoms or outbreaks in their community. Indeed, children were explicitly not tested in the beginning of the pandemic when PCR test capacities were limited. Thus, the study may have addressed an unmet need of parents to get their children tested, which was further supported by the observation that participation in the study was overwhelming.

About 70% of the positive children showed S/Co >100 in the ELECSYS test, a value approximately representing the 97th percentile of all previously available test values (provided by Roche, personal communication). We are aware that the assay is not registered for quantitative readout, nevertheless the measures give an indication for a strong antibody response in children. Compared to the 70% of seropositive children with a mild to asymptomatic course of the initial SARS-CoV-2 infection only 21% of seropositive adults with mild symptoms showed such high values in one of our studies conducted at the same time (13). A similar observation was made for the S protein based in-house ELISA test, where also high values were observed in more than half of the positively tested children. These data may suggest that children mount stronger antibody responses to SARS-CoV-2 than adults on a regular basis.

We used two different antibody tests, one directed against the N-protein and one targeting the S-protein, which explains the slight differences and discordance in test results. With two capable antibodies used for testing at the same time, we have good confidence that we were able to catch all truly seropositive children after SARS-CoV-2 infection. Interestingly, in those few cases where children were initially positive in PCR testing, approximately 30% did not show antibody responses in our tests. This is a higher percentage than observed in our studies in adults (13). Furthermore, approximately 15% of antibody positive children showed no neutralization capacity.

Taken together, it seems that children show a somewhat dichotomous response to SARS-CoV-2 in terms of antibody generation and neutralization. While a great majority mounts exceptionally high antibody responses, a significant subgroup shows no antibodies after infection or no neutralization.
systems in schools seem to be reasonable and feasible (COVID-19 occur. Alternatively, prospective PCR based test prevalence of COVID-19, if any symptoms suggestive for CoV-2 antibodies as well as children from areas with high households with COVID-19 cases on a regular basis for SARS-CoV-2 infections despite of mild or absent symptoms in children. index case, thereby not missing out on potential childhood SARS-CoV-2 infections despite of mild or absent symptoms in children. Especially with new, more contagious virus variants, infections in families become even more relevant.

Based on our results we propose to screen children from households with COVID-19 cases on a regular basis for SARS-CoV-2 antibodies as well as children from areas with high prevalence of COVID-19, if any symptoms suggestive for COVID-19 occur. Alternatively, prospective PCR based test systems in schools seem to be reasonable and feasible (16). Therefore, we would recommend longitudinal antibody testing as well as vaccination; if found to be safe; for children to ensure full protection from future disease.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Ethics Committee of the University of Regensburg (file-number: 20-1865-101). Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS
OL, GL, SG, KÜ, RW, and MK were responsible for the study design. OL, GL, HB-D, SL, AS-K, DE, MH, JN, and MK performed the data collection. AT, DP, SE, PN, NB, ES-V, PK, PS, RW, and AA carried out the laboratory analysis and the data interpretation. Data Analysis was performed by DP, SE, PN, SB, RW, and MK. OL, GL, DP, SE, SB, RW, and MK wrote this manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by institutional and charity funds, RW and KU by the Bavarian States Ministry of Science and Arts (Grant Prospective Covid-19 Cohort Tirschenreuth, TiKoCo19). Roche Diagnostics provided Elecsys Anti-SARS-CoV-2 assay free of charge.

ACKNOWLEDGMENTS
We are grateful to all participants for their bravery in giving blood and their parents for their great support, the Bavarian red cross for support in Tirschenreuth and especially Mr. Schedel; the students who helped organizing the study, packing study sets, transporting sets and samples across the study areas; the assistants and helpers in all pediatric outpatient clinics who did a tremendous job on top of their routine work; all lab personal in the involved laboratories for extra and weekend hours; and Birgit Kulawik for providing graphic design. We thank the WECARE research and development campus at the KUNO hospital St. Hedwig in Regensburg for the generous logistical support.

THE COKIBA STUDY GROUP ARE (IN ALPHABETICAL ORDER)
Bettina Aichholzer, Georg Mair, Michaela Wruk, Imike Reischl, Paediatric Office, Dr. Aichholzer, Dr. Mair, Dr. Wruk, Reischl, Bad Endorf, Germany;
David Antos, Paediatric Office Dr. Antos, Traunstein, Germany
Stephan von Koskull, Christian Becker, Paediatric Office Dr. von Koskull, Becker, Bad Aibling, Germany
Elisabeth Beer, Hubert Schirmer, Paediatric Office Dr. Beer, Dr. Schirmer, Marktredwitz, Germany
Georg Birkinger, Paediatric Office Dr. Birkinger, Wasserburg am Inn, Germany
Andreas Blueml, Paediatric Office Blueml, Trostberg, Germany
Monika Castrop, Paediatric Office Dr. Castrop, Regensburg, Germany
Jost Dieckerhoff, Paediatric Office Dr. Dieckerhoff, Rosenheim, Germany
Renate Eichhorn, Paediatric Office Dr. Eichhorn, Regensburg, Germany
Dominik Ewald, Paediatric Office Dr. Heuschmann & Dr. Ewald, Regensburg/Regenstauf, Germany
Gudrun Fleck, Alfred Heihoff, Paediatric Office Dr. Fleck, Dr. Heihoff, Regensburg, Germany

This work was supported by institutional and charity funds, RW and KU by the Bavarian States Ministry of Science and Arts (Grant Prospective Covid-19 Cohort Tirschenreuth, TiKoCo19). Roche Diagnostics provided Elecsys Anti-SARS-CoV-2 assay free of charge.

ACKNOWLEDGMENTS
We are grateful to all participants for their bravery in giving blood and their parents for their great support, the Bavarian red cross for support in Tirschenreuth and especially Mr. Schedel; the students who helped organizing the study, packing study sets, transporting sets and samples across the study areas; the assistants and helpers in all pediatric outpatient clinics who did a tremendous job on top of their routine work; all lab personal in the involved laboratories for extra and weekend hours; and Birgit Kulawik for providing graphic design. We thank the WECARE research and development campus at the KUNO hospital St. Hedwig in Regensburg for the generous logistical support.

THE COKIBA STUDY GROUP ARE (IN ALPHABETICAL ORDER)
Bettina Aichholzer, Georg Mair, Michaela Wruk, Imike Reischl, Paediatric Office, Dr. Aichholzer, Dr. Mair, Dr. Wruk, Reischl, Bad Endorf, Germany;
David Antos, Paediatric Office Dr. Antos, Traunstein, Germany
Stephan von Koskull, Christian Becker, Paediatric Office Dr. von Koskull, Becker, Bad Aibling, Germany
Elisabeth Beer, Hubert Schirmer, Paediatric Office Dr. Beer, Dr. Schirmer, Marktredwitz, Germany
Georg Birkinger, Paediatric Office Dr. Birkinger, Wasserburg am Inn, Germany
Andreas Blueml, Paediatric Office Blueml, Trostberg, Germany
Monika Castrop, Paediatric Office Dr. Castrop, Regensburg, Germany
Jost Dieckerhoff, Paediatric Office Dr. Dieckerhoff, Rosenheim, Germany
Renate Eichhorn, Paediatric Office Dr. Eichhorn, Regensburg, Germany
Dominik Ewald, Paediatric Office Dr. Heuschmann & Dr. Ewald, Regensburg/Regenstauf, Germany
Gudrun Fleck, Alfred Heihoff, Paediatric Office Dr. Fleck, Dr. Heihoff, Regensburg, Germany
SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2021.678937/full#supplementary-material

REFERENCES

1. Jones TC, Mühlemann B, Veith T, Biele G, Zuchowski M, Hofmann I, et al. An analysis of SARS-CoV-2 viral load by patient age. Infect Dis. (2020). doi: 10.1101/2020.06.08.20125484

2. Ludvigsson JF. Children are unlikely to be the main drivers of the COVID-19 pandemic - A systematic review. Acta Paediatr. (2020) 109:1525–30. doi: 10.1111/apa.15371

3. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. (2020) 382:2392–15. doi: 10.1056/NEJMoA2044446

4. Munro APS, Faust SN. Children are not COVID-19 super spreaders: time to go back to school. Arch Dis Child. (2020) 105:618–9. doi: 10.1136/archdischild-2020-319474

5. Davies P, Evans C, Kanthishathinan HK, Lille J, Brierley J, Waters G, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. (2020) 4:669–77. doi: 10.1016/S2352-4642(20)30215-7

6. Rothan HA, Byrareddy SN. The potential threat of multisystem inflammatory syndrome in children during the COVID-19 pandemic. Pediatr Allergy Immunol. (2021) 32:17–22. doi: 10.1111/pai.13361

7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. doi: 10.1056/NEJMoa204577

8. Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva AA, Borchers N, et al. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak. Pediatr Allergy Immunol. (2020) 31:841–7. doi: 10.1111/pai.13278

9. Peterhoff D, Glück V, Vogel M, Schuster P, Schütz A, Neubert P, et al. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. Infection. (2021) 49:75–82. doi: 10.1007/s15010-020-01503-7

10. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Science. (2020) 367:1049–53. doi: 10.1126/science.abb6947

Jürgen Geuder, Paediatric Office Dr. Geuder, Freilassing, Germany
Jens Grombach, Paediatric Office Dr. Grombach, Neuenstein, Germany
Peter Gutdeutsch, Florian Segerer, Paediatric Office Dr. Gutdeutsch, Dr. Segerer, Regensburg, Germany
Thomas Habash, Sonja Habash, Paediatric Office Dres. Habash, Cham, Germany
Susanne Harner, University Childrens’Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John University of Regensburg, Regensburg, Germany
Christoph Herbst, Paediatric Office Dr. Herbst, Edling, Germany
Daniela Heuschmann, Paediatric Office Dr. Heuschmann & Dr. Christoph Herbst, Paediatric Office Dr. Herbst, Edling, Germany
University of Regensburg, Regensburg, Germany
(KUNO) at the Hospital St. Hedwig
Susanne Harner, University Childrens’Hospital Regensburg
Cham, Germany
Michael Horn, Paediatric Office Dr. Horn, Schoenau am Chiemsee, Germany
Birgit Jork-Kaeferlein, Monika Schwarz, Reinhard Hopfner, Paediatric Office Dr. Jork-Kaeferlein, Dr. Schwarz, Dr. Hopfner, Prien, Germany
Guido Judex, Bastian Baumgartner, Monika Corbacioglu, Sabrina Lindner, Bettina Meinel, Alena Bauer, Hannes Löw, Annamaria Szulagyi-Kovacs, Paediatric Office Dr. Judex, Dr. Baumgartner, Dr. Corbacioglu, Dr. Lindner, Dr. Meinel, Bauer, Löw, Szulagyi-Kovacs, Regensburg, Germany
Michael Kabesch, University Childrens’Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John University of Regensburg, Regensburg, Germany
Annegret Klein, Paediatric Office Dr. Klein, Oberaudorf, Germany
Cosima Koering, Paediatric Office Dr. Koering, Altoetting, Germany
Niclas Landvogt, Claudia Soehngen, Karin Rasp, Gudrun Schick-Niedermeier, Paediatric Office Dr. Landvogt, Dr. Soehngen, Traunreut, Germany

Marinus Laub, Paediatric Office Laub, Rosenheim, Germany
Otto Laub, Paediatric Office Laub, Rosenheim, Germany
Georg Leipold, Petra Schmid-Seibold, Paediatric Office Dr. Leipold Schmid-Seibold, Regensburg, Germany
Johannes Pawlak, Michaela Reitz, Paediatric Office Dr. Pawlak, Dr. Reitz, Rosenheim, Germany
Georg Puchner, Paediatric Office Dr. Puchner, Regensburg, Germany
Christiane Razeghi, Stefan Razeghi, Paediatric Office Dres. Razeghi, Miesbach, Germany
Christine Rehe, Klaus Rehe, Paediatric Office Dres. Rehe, Kolbermoor, Germany
Matthias Scheffel, Ludwig Kaesbauer, Paediatric Office Dr. Scheffel, Dr. Kaesbauer, Muehdorf, Germany
Roland Schmid, Michael Strobelt, Paediatric Office Dr. Schmid, Dr. Strobelt, Bruckmuehle, Germany
Nina Schoetzau, Paediatric Office Dr. Schoetzau, Miesbach, Germany
Marko Senjor, Paediatric Office Dr. Senjor, Wasserburg, Germany
Michael Sperlich, Paediatric Office Dr. Sperlich, Ampfing, Germany
Guenter Theuerer, Guenter Steidle, Paediatric Office Dr. Theuerer, Dr. Steindle, Traunstein, Germany
German Tretter, Paediatric Office Dr. Tretter, Altenstadt an der Waldnaab, Germany
Victor von Arnim, Paediatric Office Dr. von Arnim, Roding, Germany
Marlene Volz-Fleckenstein, Paediatric Office Dr. Volz-Fleckenstein, Regensburg, Germany
inhibitor. *Cell.* (2020) 181:271–80.e8. doi: 10.1016/j.cell.2020.02.052

11. Schmidt F, Weisblum Y, Muecksch F, Hoffmann H-H, Michailidis E, Lorenzi JCC, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *J Exp Med.* (2020) 217:e20201181. doi: 10.1084/jem.20201181

12. Hippich M, Holthaus L, Assfalg R, Zapardiel-Gonzalo J, Kapfelsperger H, Heigermoser M, et al. A Public health antibody screening indicates a 6-fold higher SARS-CoV-2 exposure rate than reported cases in children. *Med.* (2021) 2:149–63.e4. doi: 10.1016/j.medj.2020.10.003

13. Fill Malfertheiner S, Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva AA, et al. Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: a prospective longitudinal study. *J Clin Virol.* (2020) 130:104575. doi: 10.1016/j.jcv.2020.104575

14. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. *Sci Immunol.* (2020) 5:eabd7114. doi: 10.1126/sciimmunol.abd7114

15. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med.* (2021) 27:1205–11. doi: 10.1038/s41591-021-01377-8

16. Sweeney-Reed CM, Wolff D, Niggel J, Kabesch M, Apfelbacher C. Pool testing as a strategy for prevention of SARS-CoV-2 outbreaks in schools: protocol for a feasibility study. *JMIR Res Protoc.* (2021) 10:e28673. doi: 10.2196/28673

Conflict of Interest: JN was employed by the company Maganamed Limited.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Laub, Leipold, Toncheva, Peterhoff, Neckermann, Borchers, Santos-Valente, Kheiroddin, Brandstetter, Wagner, Kabesch and Corona Virus Antibodies in Children from Bavaria (CoKiBa) Study Group. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.